Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy

Hidemi Kajimoto; Keiko Ishigaki; Kenichi Okumura; Hirofumi Tomimatsu; Makoto Nakazawa; Kayoko Saito; Makiko Osawa; Toshio Nakanishi

doi:10.1253/circj.70.991

Back

Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy

Journal article

Open access

Peer reviewed

Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy

Hidemi Kajimoto, Keiko Ishigaki, Kenichi Okumura, Hirofumi Tomimatsu, Makoto Nakazawa, Kayoko Saito, Makiko Osawa and Toshio Nakanishi

Circulation journal : official journal of the Japanese Circulation Society, Vol.70(8), pp.991-994

2006

DOI: 10.1253/circj.70.991

PMID: 16864930

Files and links (1)

url

https://doi.org/10.1253/circj.70.991View

Published (Version of record) Open Access

Abstract

In muscular dystrophy, cardiac function deteriorates with time and heart failure is one of the major causes of death. Although the combination of angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers improves cardiac function in adults, little is known about the efficacy of those drugs in patients with muscular dystrophy. The effect of the beta-blocker, carvedilol, and/or ACEI on ventricular function in patients with muscular dystrophy was studied. Carvedilol and an ACEI were given to 13 patients (ACEI group; mean age 18 years, range 7-27 years), and an ACEI only to 15 patients (carvedilol group; mean age 15 years, range 8-29 years). Diagnoses included Duchenne muscular dystrophy (n=25), Fukuyama muscular dystrophy (n=2), and Emery-Dreifuss muscular dystrophy (n=1). Echocardiographic parameters of the left ventricle were measured during the 2-3 years of follow-up. In the carvedilol group, combination therapy of carvedilol and an ACEI for 2 years resulted in a significant increase in left ventricular fractional shortening (LVFS). In the ACEI group, there was no significant change in LVFS. Left ventricular end-diastolic dimension increased in the ACEI group, but not in the carvedilol group. Carvedilol plus an ACEI improves left ventricular systolic function in patients with muscular dystrophy.

Adolescent

Adrenergic beta-Antagonists - therapeutic use

Adult

Angiotensin-Converting Enzyme Inhibitors - therapeutic use

Carbazoles - therapeutic use

Cardiac Output, Low - etiology

Cardiac Output, Low - physiopathology

Cardiac Output, Low - prevention & control

Carvedilol

Child

Disease Progression

Drug Therapy, Combination

Echocardiography

Humans

Muscular Dystrophies - complications

Muscular Dystrophies - physiopathology

Propanolamines - therapeutic use

Treatment Outcome

Ventricular Dysfunction, Left - drug therapy

Ventricular Dysfunction, Left - etiology

Ventricular Dysfunction, Left - physiopathology

Details

Title: Subtitle: Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy
Creators: Hidemi Kajimoto - Tokyo Women's Medical University
Keiko Ishigaki - Tokyo Women's Medical University
Kenichi Okumura - Tokyo Women's Medical University
Hirofumi Tomimatsu - Tokyo Women's Medical University
Makoto Nakazawa - Tokyo Women's Medical University
Kayoko Saito - Tokyo Women's Medical University
Makiko Osawa - Tokyo Women's Medical University
Toshio Nakanishi - Tokyo Women's Medical University
Resource Type: Journal article
Publication Details: Circulation journal : official journal of the Japanese Circulation Society, Vol.70(8), pp.991-994
DOI: 10.1253/circj.70.991
PMID: 16864930
NLM abbreviation: Circ J
ISSN: 1346-9843
eISSN: 1347-4820
Language: English
Date published: 2006
Academic Unit: Cardiology; Stead Family Department of Pediatrics
Record Identifier: 9984961028802771

Metrics

4 Record Views

See more details